←
Dr Rob 🫀🩺 🇦🇺1,976 posts
Dr Rob 🫀🩺 🇦🇺 avatar

Dr Rob 🫀🩺 🇦🇺

@drhungo

Primary Care Physician | Educator | ASCVD, 🫀Failure, Diabetes | Addicted to 🏃‍♂️ 🏏 &🏌🏼‍♂️ Follows Jesus, loves family, tweets≠medical advice @RACGP

◷ Joined September 2015▧ 718 Photos and videos
Sam Tsimikas, MD avatar
⟳ Dr Rob 🫀🩺 🇦🇺 retweeted
Sam Tsimikas, MD@Lpa_Doc·Nov 10

Here are my initial thoughts on Lp(a)HORIZON. This is targeted to the people to whom it matters the most, my wonderful PATIENTS over the years in my Lp(a) Clinic. I have done my best to keep you healthy, and for the most part it worked. And I think this is reflected in the results of the Lp(a)HORIZON trial. This is also for those with elevated Lp(a) that been carrying significant anxiety and concern over their elevated levels. 1- Big picture: I do not see Lp(a)HORIZON as a failure, like many Monday morning quarterbacks out there who claim to have known the results all along after all. I see it as a MAJOR SUCCESS for our patients. 2- Why? Because we learned that there may be an alternative to reduce Lp(a) mediated risk: which is to: a) keep LDL-C below 65 or lower; b) keep blood pressure at 120 or lower; c) control all other risk factors as best as possible; d) take your medicines that have proven efficacy regularly. 3- I have called Lp(a)HORIZON testing the “Lp(a) Hypothesis”. Which means we did not know if lowering Lp(a) would benefit patients. If we knew Novartis would not have spent >1 billion dollars to do the trial and the FDA would have approved the drug simply on Lp(a) lowering. 4- Why did we not see a benefit in specifically lowering Lp(a) in Lp(a)HORIZON? I think we need to go back to “first principles” in how Lp(a) causes atherothrombosis. It is a minor contributor to atherosclerosis. It is a major contributor to inflammation, via OxPL. It is also anti-fibrinolytic- NOT pro-thrombotic. That means it contributes to vulnerable plaques but not to “plaque burden”. And it contributes to a blood clots enlarging and occluding blood vessels if clots are already made, but not in making blood clots per se. 5- So if one is intensively treated to remove the nidus for vulnerable plaques and clot formation, like the patients in HORIZON (and in the ongoing trials), then Lp(a) may become quiescent. 6- In my Lp(a) Clinic, this is my summary of how I treat my patients: 75% on statin, 50% of ezetimibe and 50% (!!) on PCSK9i, along with judicious use of aspirin in primary prevention and universal use in secondary prevention. This double/triple/quadruple combo is highly effective. If I see no coronary calcium or evidence of atherosclerosis, I am not aggressive with therapy if otherwise not indicated for another reason. 7- That being said, 1 out of 8 people still had an event in Lp(a) HORIZON. So, we need to figure out why beyond classical lipids and blood pressure. I am already thinking 10 yrs ahead and will have new concepts for this issue in near future. 8- I do not think the Lp(a)HORIZON results apply to Aortic Stenosis, as this is not affected by LDL-C or for the most part aspirin, but is more @OxPL_apoB driven in people with high Lp(a). I think we owe a huge debt of gratitude for the Lp(a)HORIZON trial, to @novartis and to @ionispharma for leading the Lp(a) field. And to circle back to people with elevated Lp(a): Lp(a)HORIZON has now armed us with actionable (and inexpensive) knowledge to help people with elevated Lp(a). Take a big breath and sigh of relief, Lp(a) risk can be managed. Treat it like you do other risk factors and your prognosis will be good, like many of my Lp(a) Clinic patients. We do need to do more work to figure out, among those with elevated Lp(a), who are highest risk, and target those in future studies, I will provide more scientific comments at a later time and will be publishing my thoughts in a journal in the future. With all that said, we still don't know the physiological function of Lp(a), if any, and why >99.99% have some circulating Lp(a) and why 1 in 5 have very high levels. Knowing this may give us the ultimate answer on Lp(a) and it role not only in CV disease but also in life and longevity. Along with my collaborators, we will have something on this also in near future. Thank you all for following Lp(a)'s journey in these pages. The story is actually in the middle not at the end...a few more chapters are in the works.

Pablo Corral MD avatar
⟳ Dr Rob 🫀🩺 🇦🇺 retweeted
Pablo Corral MD@drpablocorral·Sep 5

Lp(a)HORIZON is negative. Does this mean the Lp(a) hypothesis is wrong? I don’t think we can conclude that — at least not yet. Before seeing the full data, several explanations deserve consideration: 1. Background therapy matters. In contemporary secondary prevention, aggressive LDL-C/ApoB lowering and comprehensive risk-factor control may substantially reduce the residual risk attributable to Lp(a) 2. Perhaps we are treating too late. Genetics reflects lifelong exposure to elevated Lp(a). Lowering Lp(a) for a few years after ASCVD is already established may simply be too little, too late 3. Magnitude and duration of Lp(a) lowering may matter. Not all Lp(a)-lowering strategies are equivalent. We need the achieved absolute levels, sustained reduction, adherence, and exposure over time before extrapolating HORIZON to the entire therapeutic class 4. The benefit may lie in the extreme tail. Perhaps the clinically modifiable risk is concentrated among patients with very high Lp(a). The prespecified analyses at higher baseline Lp(a) levels will be particularly important 5. Lp(a) concentration may not tell the whole biological story. OxPL burden, apo(a) isoform size, and particle composition may influence pathogenicity. Two patients with the same Lp(a) concentration may not necessarily carry the same Lp(a)-mediated risk 6. Could the endpoint dilute the signal? Lp(a) may preferentially affect coronary and recurrent events. Individual MI/revascularization and total-event analyses may tell a different story than first 4-point MACE. 7. Genetics may predict causality better than therapeutic effect size. Mendelian randomization reflects decades of exposure. It should not automatically be translated into the magnitude of benefit expected from a relatively short pharmacological intervention 8. Are we targeting Lp(a), but not necessarily its most pathogenic cargo? Lp(a) is the major carrier of oxidized phospholipids (OxPL), which contribute to vascular inflammation, plaque vulnerability and thrombogenicity. Lp(a) concentration may therefore be an imperfect surrogate for its biological activity. The relationship between Lp(a) lowering, OxPL reduction and clinical benefit deserves particular attention 9. Could intensive antiplatelet therapy attenuate the atherothrombotic component of Lp(a) risk? Lp(a) may promote thrombosis through platelet activation, coagulation and formation of more lysis-resistant clots. OxPL can also interact with platelet receptors. In a secondary-prevention population such as HORIZON, where aspirin and other antiplatelet therapies are extensively used, part of this pathway may already be pharmacologically suppressed — potentially leaving less Lp(a)-mediated risk for pelacarsen to modify 10. Low event rates may be part of the answer. Despite enrolling 8,323 high-risk secondary-prevention patients, HORIZON required a remarkably long follow-up to accrue the prespecified number of events. This suggests that contemporary secondary prevention substantially reduced the absolute residual risk available for Lp(a) lowering to modify. Nuestro análisis previo ya señalaba que la menor tasa de eventos era una de las principales amenazas para el estudio 11. Was HORIZON powered for a larger effect than the true pharmacological effect? An event-driven design protects statistical power if the required number of events is reached — but only for the effect size assumed in the design. If short-term pharmacological Lp(a) lowering produces a much smaller benefit than predicted from lifelong genetic exposure, even a trial of >8,000 patients may struggle to demonstrate it 12. The long time required to reach the endpoint may itself be biologically informative. These were patients with established ASCVD and very high Lp(a), yet events accumulated more slowly than anticipated. Perhaps elevated Lp(a) identifies substantial lifetime risk, but contributes less modifiable short-term residual risk once other major pathways are aggressively treated. 13. Six years is a long time for background therapy to evolve. During prolonged follow-up, increasing use of PCSK9 inhibitors, ezetimibe, bempedoic acid, inclisiran, SGLT2 inhibitors and GLP-1 receptor agonists — together with improved BP and antithrombotic management — may have progressively reduced event rates in both groups. These potential therapeutic “drop-ins” were already a concern before the results were known 14. First events may not capture the entire Lp(a) burden. Lp(a) could influence recurrent coronary events and total atherosclerotic burden more strongly than time-to-first MACE. Analyses of total/recurrent events will therefore be particularly important 15. The “risk-factor exhaustion” hypothesis. With LDL-C around 65 mg/dL, intensive lipid-lowering therapy, antiplatelet treatment, good BP control and contemporary diabetes therapy, multiple atherogenic and thrombotic pathways were already being targeted. HORIZON may therefore have tested Lp(a) lowering in a setting where relatively little modifiable residual risk remained. The published baseline characteristics already showed how intensively treated this population was 16. Perhaps the effect of Lp(a) depends on the surrounding biological environment. The clinical consequences of Lp(a) may result from the interaction of apoB particle burden + OxPL-mediated inflammation + thrombosis/impaired fibrinolysis. With LDL/ApoB aggressively lowered and most patients receiving antiplatelet therapy, two important components of that environment may already have been attenuated. Maybe the key question is not simply whether Lp(a) is causal, but WHEN, in WHOM, and HOW MUCH it needs to be lowered to change clinical outcomes. Until we see the full HORIZON dataset, declaring the Lp(a) hypothesis dead seems premature. #Lp(a) #LipoproteinA #ASCVD #Cardiology #Atherosclerosis #Horizontes novartis.com/news/media-rele…

Gregg Fonarow MD avatar
⟳ Dr Rob 🫀🩺 🇦🇺 retweeted
Gregg Fonarow MD@gcfmd·Sep 2

🫀 Statins for primary prevention: 4 RCTs, 3 decades AFCAPS→JUPITER→HOPE-3→STAREE 📉 24–44% ↓ major CV events Even at baseline LDL (108 mg/dL) No heterogeneity across subgroups in RRR 
🟰 Safety ≈ placebo, few exceptions 
⚖️ Benefits ≫ risks 💊 cost $30/year

Post attachment
Dr Ihab Suliman avatar
⟳ Dr Rob 🫀🩺 🇦🇺 retweeted
Dr Ihab Suliman@IhabFathiSulima·Sep 1

🚨 10 striking conclusions from ESC 2026 1. HFmrEF is essentially gone. ESC now defines HFrEF as LVEF <50% and HFpEF as ≥50%. 2. MRAs have broken the EF barrier. Mineralocorticoid receptor antagonists now have a Class I recommendation in chronic HF irrespective of LVEF. Semaglutide/tirzepatide receive Class IIa recommendations for HFpEF with obesity. 3. SINGLE-AF: anticoagulation may start earlier than we thought. In AF patients at intermediate stroke risk, DOAC therapy reduced adverse clinical outcomes by 69% versus no anticoagulation. 4. Severe TR is no longer just “give diuretics and watch.” TRIC-I-HF: transcatheter tricuspid repair reduced HF hospitalisation and all-cause mortality compared with medical therapy alone. 5. Unexplained syncope deserves early prolonged ECG monitoring. ASPIRED: immediate 14-day monitoring did not prevent recurrent syncope, but substantially improved arrhythmia diagnosis/treatment and was associated with lower mortality. 6. Intermediate–high-risk PE may be entering the catheter era. PRAGUE-26: catheter-directed thrombolysis improved short-term clinical outcomes versus anticoagulation alone, without an obvious major bleeding penalty. 7. Cardiac arrest + no STEMI ≠ automatic immediate cath lab. DISCO: immediate angiography after OHCA without ST elevation did not improve 30-day survival. 8. Being ≥70 is not a reason to abandon primary-prevention statins. STAREE: atorvastatin reduced major cardiovascular events by about 30% in older adults without known CVD, although disability-free survival was unchanged. 9. AF ablation has a surprisingly large placebo component for symptoms. PVI-SHAM-AF: ablation reduced AF recurrence, yet improvement in AF-related quality of life was not significantly greater than sham treatment. 10. Even the definition of MI has changed. The 5th Universal Definition of MI replaces the traditional numbered framework with primary MI, secondary MI and procedure-related MI, while incorporating sex-specific troponin thresholds and greater use of imaging. 🔥 The one-line ESC 2026 message: Treat HF across the EF spectrum, anticoagulate selected AF patients earlier, intervene on TR, monitor syncope sooner—and stop rushing every post-arrest patient without STEMI to the cath lab.

Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦 avatar
⟳ Dr Rob 🫀🩺 🇦🇺 retweeted
Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦@DrMarthaGulati·Aug 31

#CorCal #ESCCongress #CVPrev 🫀5,772 primary prevention pts (52% women) → CAC-guided vs PCE-guided statin therapy ➡️At 4.2 yrs: MACE 2.7% vs 2.7% HR 0.99 (95% CI 0.71–1.38)- no diff ➡️Noninferiority NOT met due to low event rates but CAC recommended fewer statins with better adherence: 62% CAC 🆚23% PCE So, Risk Scores 🆚 #CAC? What’s the best choice?

C. Michael Gibson MD avatar
⟳ Dr Rob 🫀🩺 🇦🇺 retweeted
C. Michael Gibson MD@CMichaelGibson·Aug 29

A-CLOSE trial: For high ischemic risk patients 12 months after DES implantation, clopidogrel monotherapy was non-inferior to extended DAPT for net adverse clinical events at 2 years, with reduced bleeding but increased ischemic risk. Download slides here: clinicaltrialresults.org/wp-…

Post attachmentPost attachmentPost attachmentPost attachment
Pablo Corral MD avatar
⟳ Dr Rob 🫀🩺 🇦🇺 retweeted
Pablo Corral MD@drpablocorral·Aug 29

☝️Atherosclerosis starts earlier than we think 👉New data from the REACT study, published in NEJM, provide a striking picture of silent atherosclerosis across adult life: 1️⃣ 16,808 adults, aged 18–70 years, without known ASCVD. 2️⃣ Multimodal imaging included 3D carotid and femoral ultrasound plus coronary CT angiography. 3️⃣ Silent atherosclerosis was present in 57.1% of participants. 4️⃣ Even at 18–29 years, plaque was already present in 8.7% of men and 6.7% of women. 5️⃣ By age 30–39, prevalence reached 34.6% in men and 21.3% in women. 6️⃣Atherosclerosis appeared 5–10 years earlier in men, while women showed a later but steeper rise in midlife. 7️⃣ In younger adults, disease was usually peripheral and single-territory, especially carotid; with age, plaque burden increased exponentially and disease became increasingly multiterritorial. 8️⃣ ☝️Importantly, CAC = 0 did not exclude coronary plaque: among 30–39-year-olds with coronary atherosclerosis, ~42% of men and ~48% of women had zero coronary calcium 9️⃣ SCORE2 showed major discordance with actual disease burden: high SCORE2 had only 1.9% sensitivity for silent atherosclerosis. ☝️Key message: low short-term cardiovascular risk does not mean absence of atherosclerosis. 👉Risk scores estimate events. Imaging detects disease. REACT reminds us that prevention should begin long before cardiovascular risk becomes “high.” 🔗 nejm.org/doi/full/10.1056/NE… @society_eas

Post attachmentPost attachmentPost attachmentPost attachment
Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦 avatar
⟳ Dr Rob 🫀🩺 🇦🇺 retweeted
Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦@DrMarthaGulati·Aug 29

🫀 #STAREE at #ESCCongress Do statins benefit healthy adults ≥70 years? Yes! Atorvastatin 40 mg vs placebo, ~6 years. ❤️ Major CV events: 10.9 vs 15.5/1,000 person-years HR 0.70 (95% CI 0.61–0.82) ✅ 🧠 Disability-free survival (death, dementia or persistent disability): 21.6 vs 23.0/1,000 person-years HR 0.94 (0.84–1.05) ❌ Takeaway: In older adults without established CVD, statin therapy produced a substantial 30% relative reduction in major CV events, but did not significantly prolong disability-free survival. 📄 @NEJM nejm.org/doi/abs/10.1056/NEJ… #Statins #Prevention #CardioTwitter

Dr Rob 🫀🩺 🇦🇺 avatar
Dr Rob 🫀🩺 🇦🇺@drhungo·Jul 7

🚨Triglycerides are the canary in the coal mine 🚦 They signal underlying metabolic dysfunction & increased exposure to apoB-containing lipoproteins 👉🏼 the true drivers of progressive ASCVD 🗺️ We’ve distilled the latest evidence into one practical clinical roadmap for everyday practice 👍🏼 🧵 1/3 @ACCinTouch @escardio @ESC_Journals @EAS_Society @American_Heart @JACCJournals @EuropeanHeartJ #CardioX #CardioTwitter #Lipidology #PreventiveCardiology #MedTwitter #FOAMed #MEDed

Post attachment
Pablo Corral MD avatar
⟳ Dr Rob 🫀🩺 🇦🇺 retweeted
Pablo Corral MD@drpablocorral·Apr 11

👉 We spend decades arguing about how low to push LDL-C 👆 Almost no one asks the obvious question: 🤔 How much LDL-C did our ancestors actually have? The evidence exists — five independent lines, all converging on the same uncomfortable answer. 1️⃣ The term newborn. Before any dietary or metabolic influence, a healthy neonate arrives with LDL-C of ~30–50 mg/dL. That is the LDLR operating without environmental interference. Everything that rises after birth is acquired. 2️⃣ The Tsimane (Kaplan et al., Lancet 2017) — forager-horticulturalists of the Bolivian Amazon — have a LDL-C between 70 to 90 mg/dL and the lowest prevalence of coronary atherosclerosis ever recorded in any human population. Five times less than the U.S. in adults over 75. And their LDL is rising as roads and processed food arrive. 3️⃣ PCSK9 loss-of-function variants. African American carriers of nonsense mutations (Y142X/C679X, ~2% frequency): −28% LDL-C and −88% CHD risk over 15 years (Cohen et al., NEJM 2006). Homozygous LOF carriers live with LDL-C of ~15–30 mg/dL. Perfectly healthy. Nature already ran the trial. 4️⃣ Evolutionary genetics. Recent positive selection signals exist on gain-of-function PCSK9 variants that raise LDL-C — likely adaptive in food-scarce ancestral environments. Modern hypercholesterolemia is not "normal." It is an ancestral survival advantage turned pathological by evolutionary mismatch. 5️⃣ Great apes in natural habitat: ~40–70 mg/dL LDL-C. Same genome. Different environment. 👆 Bonus — Lp(a). The KIV-2 repeat expansion that raises Lp(a) is a derived, recent variant. Low-Lp(a) alleles are ancestral. Elevated Lp(a) is a textbook antagonistic pleiotropy signal — possibly protective against bleeding early in life, atherogenic over decades 📍The convergent estimate: ancestral LDL-C was ~30–70 mg/dL. 📍An LDL-C of 130 mg/dL is not "normal." It is normal for a Western society in evolutionary mismatch. Targets of <55 mg/dL in high-risk patients — which still feel aggressive to many clinicians — are, ironically, closer to the ancestral phenotype than what we call "normal LDL" in daily practice. 🤔 The question is not "is it safe to lower LDL this much?" The question is: why did we let it rise this high? @society_eas @nationallipid

Post attachment